However, due to differences in cancer trajectories in patients with NSCLC using EGFR-TKIs, understanding patient perceptions regarding oral cancer medications can help tailor evidence-based practice with increasing oncology care. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.